Clinical features of cGVHD according to transplantation type
| . | PBSC (n = 31) . | BM (n = 19) . | P . |
|---|---|---|---|
| Immunosuppression withdrawal/restarting (%)3-150 | 12 (39) | 1 (5) | .02 |
| Median time between immunosuppression withdrawal/restarting, mo (range)3-150 | 3.8 (2-11) | 24 | |
| Second-line immunosuppressive regimen (%) | 16 (52) | 4 (21) | .03 |
| Skin (%) | |||
| Lichenoid lesions | 22 (71) | 15 (79) | NS |
| Sclerodermatous lesions | 9 (29) | 4 (21) | |
| Mouth (%) | 29 (93) | 15 (79) | NS |
| Eyes (%) | 22 (71) | 7 (37) | .02 |
| Liver (%) | 20 (64) | 8 (42) | |
| Median time to normalization of serum bilirubin, mo (range) | 22 (6-49) | 14 (8-36) | .08 |
| Pulmonary (%) | 3 (10) | 0 | |
| Vaginal (%) | 3 (10) | 2 (13) | NS |
| Other (%) | 5 (16) | 0 |
| . | PBSC (n = 31) . | BM (n = 19) . | P . |
|---|---|---|---|
| Immunosuppression withdrawal/restarting (%)3-150 | 12 (39) | 1 (5) | .02 |
| Median time between immunosuppression withdrawal/restarting, mo (range)3-150 | 3.8 (2-11) | 24 | |
| Second-line immunosuppressive regimen (%) | 16 (52) | 4 (21) | .03 |
| Skin (%) | |||
| Lichenoid lesions | 22 (71) | 15 (79) | NS |
| Sclerodermatous lesions | 9 (29) | 4 (21) | |
| Mouth (%) | 29 (93) | 15 (79) | NS |
| Eyes (%) | 22 (71) | 7 (37) | .02 |
| Liver (%) | 20 (64) | 8 (42) | |
| Median time to normalization of serum bilirubin, mo (range) | 22 (6-49) | 14 (8-36) | .08 |
| Pulmonary (%) | 3 (10) | 0 | |
| Vaginal (%) | 3 (10) | 2 (13) | NS |
| Other (%) | 5 (16) | 0 |
These patients had recrudescence of cGVHD following total withdrawal of the immunosuppressive therapy, thus leading to the restarting of immunosuppressive therapy.
NS indicates not significant.